Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-30655665

ABSTRACT

RATIONALE: In symptomatic patients with COPD, the decision whether to initiate maintenance treatment with a single agent or a combination of long-acting bronchodilators remains unclear. OBJECTIVE: To investigate whether baseline symptomatic status influences response to tiotropium/olodaterol treatment. MATERIALS AND METHODS: Post hoc analysis of the randomized OTEMTO® studies (NCT01964352; NCT02006732), in which patients with moderate-to-severe COPD received placebo, tiotropium 5 µg, tiotropium/olodaterol 2.5/5 µg, or tiotropium/olodaterol 5/5 µg once daily for 12 weeks via the Respimat® inhaler (Boehringer Ingelheim, Ingelheim am Rhein, Germany). Impact of baseline symptomatic status (modified Medical Research Council [mMRC] score) on response to treatment with tiotropium/olodaterol 5/5 µg, tiotropium 5 µg, or placebo at Week 12 was assessed by St George's Respiratory Questionnaire (SGRQ) total score and response rate, transition dyspnea index (TDI) focal score and response rate, and trough forced expiratory volume in 1 second response. RESULTS: Tiotropium/olodaterol improved SGRQ total scores and response rates compared with placebo and tiotropium for patients with baseline mMRC scores 0-1 and ≥2. For tiotropium/olodaterol vs tiotropium, greater improvements were observed for patients with mMRC ≥2 (SGRQ score adjusted mean treatment difference -3.44 [95% CI: -5.43, -1.46]; P=0.0007; SGRQ response rate ORs 2.09 [95% CI: 1.41, 3.10]; P=0.0002). Dyspnea, measured by TDI score, was consistently improved with tiotropium/olodaterol vs placebo for patients with mMRC scores 0-1 and ≥2 (adjusted mean treatment difference 1.63 [95% CI: 1.06, 2.20]; P<0.0001 and 1.60 [95% CI: 1.09, 2.10]; P<0.0001, respectively). In patients with mMRC scores 0-1 and ≥2, tiotropium/olodaterol consistently improved TDI response rate and lung function vs placebo and tiotropium. CONCLUSIONS: Patients with COPD with more severe baseline dyspnea appear to derive greater health status benefit with tiotropium/olodaterol compared with tiotropium alone.


Subject(s)
Adrenergic beta-2 Receptor Agonists/therapeutic use , Benzoxazines/therapeutic use , Bronchodilator Agents/therapeutic use , Cholinergic Antagonists/therapeutic use , Lung/drug effects , Pulmonary Disease, Chronic Obstructive/drug therapy , Tiotropium Bromide/therapeutic use , Adrenergic beta-2 Receptor Agonists/adverse effects , Aged , Benzoxazines/adverse effects , Bronchodilator Agents/adverse effects , Cholinergic Antagonists/adverse effects , Drug Combinations , Dyspnea/diagnosis , Dyspnea/drug therapy , Dyspnea/physiopathology , Female , Forced Expiratory Volume , Health Status , Humans , Lung/physiopathology , Male , Middle Aged , Multicenter Studies as Topic , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/physiopathology , Randomized Controlled Trials as Topic , Recovery of Function , Severity of Illness Index , Time Factors , Tiotropium Bromide/adverse effects , Treatment Outcome , Vital Capacity
SELECTION OF CITATIONS
SEARCH DETAIL
...